SALT LAKE CITY --(BUSINESS WIRE)-- Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it held a special meeting of stockholders at which the stockholders approved a reverse stock split of the Company's common stock at a ratio of between 1 for 50 and 1 for 60 to be selected at the sole discretion of the Company's board of directors and on a record date to be determined by the board of directors in the near future. On the record date the shares will begin trading based on the reverse split ratio, this will also cure the Company's previously announced Authorized Share Failure and the Series C Warrants will become exercisable for the following 25 trading days as previously announced on December 7, 2015 . Shareholders did not approve the proposal to increase the Company's authorized shares from 200 million to 950 million.
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
